RMD · News · 20260807N
Astral Ventilator Sales Suspension
RESMED INC · 2026-08-07 · Importance 78 · Surprise 100 · In source text
ResMed suspended new sales of its Astral ventilators after an FDA recall. The company expects no Astral ventilator sales in fiscal 2027 while it repairs existing devices. The action is expected to reduce revenue by approximately $75 million and diverts resources toward device remediation.
Key facts
- ResMed's FY2027 guidance assumes no Astral ventilator sales in fiscal 2027, reducing expected revenue by an estimated $75 million. source
- The revised guidance assumes no Astral ventilator sales in fiscal 2027 as resources are diverted to repair existing devices. source
- Analysts estimated the Astral field safety action will impact revenue by $75 million. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | probable | — | ResMed's FY2027 guidance assumes no Astral ventilator sales in fiscal 2027, reducing expected revenue by an estimated $75 million. |